Letter: Do selective serotonin reuptake inhibitors cause suicide?: Antidepressant prescribing to children and adolescents by GPs has fallen since CSM advice by Murray, ML
Do selective serotonin reuptake inhibitors cause suicide?
Risk of suicide should be assessed for
whole class of antidepressants
Editor—Gunnell et al’s report on suicide
risk with selective serotonin reuptake inhibi-
tors (SSRIs) raises several issues.1
Firstly, clinicians have observed that the
first weeks of treatment of severe depression
with an antidepressant are accompanied by
a higher risk of suicide because of a drug
induced motor disinhibition that is not yet
accompanied by mood improvement.2
Secondly, the authors’ finding of a trend
towards a protective effect of SSRIs against
suicidal thoughts (odds ratio 0.77) com-
pared with a trend towards an increased risk
of self harm (odds ratio 1.57)
is paradoxical.
More surprising is the
heterogeneity of results
among SSRIs. Why would
sertraline show a protective
effect for suicidal thoughts
and simultaneously increase
the risk of self harm? The
risk difference between cita-
lopram and its active
S-enantiomere, escitalo-
pram, is also strange. No
strong biological rationale
can explain such heteroge-
neity among drugs with the
same mechanism of action.
Thirdly, the authors mention that the
Medicine and Healthcare products Regula-
tory Agency found little evidence for a risk
difference between SSRIs and the other
antidepressants. The two accompanying
papers show that the suicidal risk seems
similar for serotoninergic and tricyclic
antidepressants.3 4 The risk of suicide must
be assessed for the whole class of anti-
depressants.
The next stage would be to measure the
risk of suicide according to the time since
starting an antidepressant. Initially, the risks
are higher than the benefits. To confirm old
clinical observations by evidence based
methods would be interesting and useful.
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Figures look doubtful
Editor—Gunnell et al offer figures for
suicide with selective serotonin reuptake
inhibitors (SSRIs).1 However, in the expert
working group’s report on
SSRIs,2 the table for citalo-
pram indicates no suicide in
the placebo group. Data on
paroxetine are not available
from the report, but prior
submissions indicate four
suicides with paroxetine
(CSM Expert Working
Group on the Safety of
SSRIs, unpublished data,
2003). Gunnell et al note
three suicides in the placebo
group during the withdrawal
phase, but a 1991 review of
the safety of paroxetine does
not indicate that these happened in the
withdrawal phase of placebo controlled
trials.3 If Gunnell et al are relying on a com-
pany submission these figures must be in
some doubt.
Twelve suicides may have occurred in
23 804 patients taking SSRIs and six in
17 022 taking placebo, an odds ratio of
1.43; or possibly 12 suicides with SSRIs and
three with placebo, an odds ratio of 2.86.
Leaving paroxetine out, the figures become
eight suicides in 15 323 patients taking
SSRIs and three in 11 214 patients taking
placebo, an odds ratio of 1.96. Adding in
venlafaxine and mirtazapine gives 16
suicides in 23 885 patients taking anti-
depressant and three in 14 564 taking
placebo, an odds ratio of 3.1.
If antidepressants reduce the risk of sui-
cide in some patients an odds ratio of 1.0 for
suicide points to a clear risk. A randomised
controlled trial with a challenge-dechallenge
design and a rating scale sensitive to suicidal
ideation might need less than 100 patients
to firm up on any risk of induced suicidality.
Eli Lilly designed such a trial in conjunction
with the US Food and Drug Administration
in 1990.
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Authors’ reply to Curtin and Schulz, and
Healy
Editor—We agree with Curtin and Schulz
that drug induced motor disinhibition
before mood improvement is a possible
explanation for an excess of suicidal
behaviour in the early weeks of antidepres-
sant treatment.1 2
Regarding their second point, we cau-
tion against over-interpreting differences in
the pooled odds ratios for self harm and sui-
cidal thoughts or the odds ratios for
different selective serotonin reuptake inhibi-
tors (SSRIs) in relation to the same end
points. Odds ratios are estimated from a
small number of events, and confidence
intervals overlap.
Lastly, we agree that there is little
evidence for a difference in risk between dif-
ferent classes of antidepressant.3–5
Healy is concerned about two of the
numbers in our meta-analysis. We confirm
that the expert working group’s report
included one suicide among patients treated
with placebo in placebo controlled trials of
citalopram for depression (table 7.16, page
84).5 Likewise data on paroxetine suicides
were reported (section 7.2.1, page 74).5 As
we said in our paper, three of the four
suicides in the placebo controlled trials of
paroxetine (all in the placebo arm) occurred
in the period after treatment. We therefore
carried out sensitivity analysis to assess the
effect on the pooled odds ratio of excluding
these deaths (plus the suicide after treatment
with escitalopram). This showed an increase
in the odds ratio for suicide to 1.24. Healy’s
odds ratios are not calculated by using meta-
analytic approaches for pooling data for
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each SSRI and so are not directly compara-
ble with our figures.
We communicated Healy’s concern with
the paroxetine suicide data to the Medicines
and Healthcare products Regulatory
Agency (MHRA). In further consultation
with the licence holder, the agency confirms
that the four suicides in adult placebo
controlled randomised trials of paroxetine
were as described above (MHRA, personal
communication, 2005).
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Discrediting old drugs may be useful in
marketing new ones
Editor—Fergusson et al report the associa-
tion between suicide attempts and use of
selective serotonin reuptake inhibitors
(SSRIs).1 A causal link between use of an
SSRI and self harm would have drastic clini-
cal implications for health services. The
extra monitoring might make using antide-
pressants wholly impractical in a risk averse
service.
The reported incidence of self harm in
these studies, with estimates of 0.05-0.001%,
is remarkably low. Even during a short trial,
such a low incidence among patients with
severe depression is not credible. The surely
unique finding that rates of fatal and
non-fatal self harm are identical among pla-
cebo treated patients further emphasises
how unsustainable these reported figures
must be. It is perhaps unsurprising that in
studies designed to evaluate not self harm
but efficacy, acts of self harm will be
under-reported.
Under-reporting is likely to be more
common among placebo treated patients.
Although the methods of self harm are not
stated, overdose of trial tablets might
account for several of these reports. The trial
treatments are unequal since SSRIs will
cause physical effects (gastrointestinal dis-
turbance) that might prompt attendance at
an emergency department. Placebo should
provoke no such reaction and thus less need
to report such an act of self harm.
Such data have not emerged to a
barrage of opprobrium from the pharma-
ceutical industry. Although popular and
endorsed in recent guidelines from the
National Institute for Clinical Excellence,2
SSRIs no longer have novelty value and
are rapidly losing their patents. Data
that discredit such old drugs may serve
well in marketing the new generation of
antidepressants.
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Let’s keep it in perspective
Editor—The news media’s preoccupation
with whether antidepressants provoke sui-
cidal behaviour has generated apprehension
in the general public, and clinicians increas-
ingly see patients resistant to taking selective
serotonin reuptake inhibitors (SSRIs) even
though they might benefit. The meta-
analysis by Fergusson et al reported an
excess of suicidal attempts with SSRIs v pla-
cebo and, initially, an alarming sevenfold
odds ratio for fatalities compared with tricy-
clic antidepressants [subsequently corrected
to 1.08 (0.28 to 4.09), see correction 19
March, p 653].1
A statistical excess of suicidal attempts
in studies of SSRIs v placebo has been pre-
viously reported and was reasonably
explained in the accompanying editorial by
Cipriani et al.2 3 However, the whole debate
loses sight of the fact that the underlying
trials were never designed to assess suicidal-
ity as an outcome but to satisfy regulatory
agencies about efficacy. Retrospective
counts of incidents of deliberate self harm
or attempted suicide are extremely unreli-
able in such studies; fatalities obviously less
so (but no excess has surfaced among
these). The randomisation process in
smaller trials may be questioned, and
heterogeneity could have precluded some
of the trials in the current meta-analysis.
Prospective studies with suicidality as the
outcome variable are needed to lay such
issues to rest, but these have rarely been
done, for valid reasons.4
In any case, odds ratios (or other ratios)
alone do not give an indication of absolute
risk: the number needed to harm (NNH)
should also be examined. In the current
meta-analysis, an NNH of 708 compares
quite favourably with others in medicine—
for example, 179 in the CAPRIE trial (com-
paring clopidogrel with aspirin for stroke
patients).5
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Data seem to be incorrect
Editor—Fergusson et al report that the risk
of suicide attempts is significantly greater for
patients enrolled in short term randomised
controlled trials of selective serotonin
reuptake inhibitors (SSRIs) than with pla-
cebo (odds ratio 2.28, P < 0.02) and other
interventions (not including tricyclics) (odds
ratio 1.94).1 They are also one of the few
groups to report that completed suicides
(fatal attempts) were also higher with SSRIs
than tricyclics (odds ratio 7.27 [corrected to
1.08 (0.28 to 4.09), see correction, 19 March,
p 653]). This seems to have led Cipriani et al
to say that there is almost a double risk of
fatal and non-fatal risk of suicide for people
taking SSRIs.2
An increased risk of fatal overdoses
when using SSRIs is hard to understand,
particularly when the comparison is
tricyclics, given their acknowledged toxicity
in overdose.3–5 I therefore rechecked the
odds ratios from the data given by
Fergusson et al and found most of them to
be incorrect.
For example, they say that the odds ratio
of suicide attempts in SSRIs compared with
others is 1.94; but with 27 SSRI cases out of
4130 treated patients and 18 control cases
out of 4233 treated patients the odds ratio is
1.54 (95% confidence interval 0.85 to 2.8)—
that is, non-significant. Changing the
denominator to 8856 and 9059 (all trials)
makes no difference to the result.
Similarly, Fergusson et al say that the
odds ratio for non-fatal attempts was 2.25
whereas I calculate it at 1.89 (0.96 to 3.73),
again non-significant. Perhaps most incom-
prehensibly regarding the odds of com-
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pleted suicide and tricyclics, the number of
SSRI cases is five and that of tricyclic antide-
pressant cases is four—a non-significant
difference.
In conclusion, either most of the raw
data printed in table 1 are wrong or one of
us has miscalculated dramatically.
Alex J Mitchell consultant in liaison psychiatry
Leicester General Hospital, Leicester LE5 4PW
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Competing interests: None declared.
1 Fergusson D, Doucette S, Cranley Glass K, Shapiro S,
Healy D, Hebert P, et al. Association between suicide
attempts and selective serotonin reuptake inhibitors:
systematic review of randomised controlled trials. BMJ
2005;330:396. (19 February.)
2 Cipriani A, Barbui C, Geddes JR. Suicide, depression, and
antidepressants. BMJ 2005;330:373-4. (19 February.)
3 Cheeta S, Schifano F, Oyefeso A, Webb L, Ghodse AH.
Antidepressant-related deaths and antidepressant pre-
scriptions in England andWales, 1998-2000.Br J Psychiatry
2004;184:41-7.
4 Henry JA, Alexander CA, Sener EK. Relative mortality
from overdose of antidepressants. BMJ 1995;310:221-4.
5 Shah R, Uren Z, Baker A, Majeed A. Deaths from
antidepressants in England and Wales 1993-1997: analysis
of a new national database. Psychol Med 2001:31:1203-121.
Authors’ reply to Jones, Sakinofsky and
Streiner, and Mitchell
Editor—The low rates of attempted suicide
may be the result of several factors. Most
studies did not enrol patients at immediate
risk of suicide, and 59% of studies (414/702)
were conducted in clinical indications other
thanmajor depression. The greatest contrib-
uting factors may be the under-reporting
and non-reporting of events. Of the 702 tri-
als, 345 did not provide documentation on
suicide attempts.
Given the seriousness of attempted
suicide, the expectation that patients in trials
be well monitored, and a well documented
possible association between treatment with
selective serotonin reuptake inhibitors
(SSRIs) and suicidality, it is disturbing that
fatal and non-fatal suicide attempts were not
apparently better reported. We have no
empirical evidence that under-reporting
may be differential because of side effects,
prompting closer external monitoring of
patients taking SSRIs. Good clinical trial
management dictates that blinded investiga-
tors monitor all patients for all serious
adverse events.
We agree that most trials evaluated were
not intended to assess suicidality and
strongly advocated that large clinical trials
with clinically meaningful outcomes are
needed to help clinicians and regulators.
Given that SSRIs reduce depression and
depression is associated with suicidality, we
are surprised that trials assessing the
effectiveness of SSRIs in reducing suicidal-
ity have not been conducted. An appropri-
ately designed, randomised controlled trial
along with validated measures of assessing
suicidality would not require many patients
to examine, safely, any risk and might
enable antidepressants to be used more
effectively and safely. Such a trial and rating
scale were designed by Eli Lilly with the
Food and Drug Administration in 1991
(details forwarded on request).
Ignoring individual trials and calculating
summary statistics from lumped data, as
Mitchell has done, is an incorrect approach
to meta-analysis. Nowhere in our Methods
section do we state that we calculated odds
ratios from the aggregated data. Instead, we
conducted meta-analyses of randomised
controlled trials using Peto’s method for cal-
culating odds ratios of rare event data.
Failing to preserve the randomisation of
subjects at the trial level introduces bias and
confounding.1 Furthermore, simply calculat-
ing odds ratios from aggregated data fails to
account for the influence of chance in small
trials. By weighting each study by its
precision, smaller trials have less influence
than larger trials.
Given the enormous number of SSRIs
prescribed, we maintain that a number
needed to harm as large as 684 represents a
public health concern. For every 1 million
prescriptions, this translates into more than
1450 excess suicide attempts compared with
those receiving placebo.
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Suicide rate of 15% in editorial is
misleading
Editor—Cipriani et al in their editorial
make many sound points about the risks
and benefits of antidepressants.1 However,
they say that up to 15% of patients
with unipolar depression eventually com-
mit suicide. This implies that 15% is a
reasonable estimate, rather than a gross
overestimate based on very unrepresenta-
tive samples.
How many casual readers will be misled
by this statement, which reinforces a
stubbornly persistent myth?
Melissa K Raven lecturer, public health
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Authors’ reply to Raven
Editor—Depressed people are at increased
risk of suicide, and our aim was to draw
attention to the clinical severity of the prob-
lem, focusing on the real clinical dilemmas.
Accurate estimation of the risk of suicide in
depressed people is a crucial clinical issue.
Research has been trying to measure this
phenomenon for more than 30 years, and
contrasting figures have been reported.1–3
The true suicide risk for the average patient
remains uncertain.4 In our editorial we used
the sentence “up to 15% of patients with
unipolar depression eventually commit
suicide” to emphasise the need to take this
outcome very seriously, and we cited a paper
by Davies et al to acknowledge how
uncertain the exact risk remains.5
Additionally, we wanted to highlight an
apparent existing paradox in the role of
antidepressants in the treatment of depres-
sion. Instead of debating which antidepres-
sants are more effective in reducing the risk
of suicide by treating the depressive
symptoms effectively, much current litera-
ture focuses on which antidepressants are
less dangerous in causing suicide as an
unwanted effect of treatment. This paradox
indicates that further research is urgently
needed to shed light on these issues.
In the meantime, doctors need to keep
up to date with emerging research
findings,w1-w3 bearing in mind that untreated
or inadequately treated individuals with
moderate to severe depression are at
increased risk of suicide.
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Antidepressant prescribing to children
and adolescents by GPs has fallen since
CSM advice
Editor—The decline in routine prescribing
of antidepressants in children and adoles-
cents expected by Cipriani et al has already
started.1 We analysed antidepressant pre-
scribing by general practitioners between 1
January 2000 and 31 December 2004 using
the IMS Disease Analyzer-Mediplus data-
base to examine the effects of the UK Com-
mittee on Safety of Medicines’ advice on
antidepressant prevalence.2 3
Antidepressant use increased between
2000 and 2002 (5.4 per 1000 to 6.6/1000);
the prescription of selective serotonin
reuptake inhibitors (SSRIs) and venlafaxine
rose. Between 2002 and 2004 antidepres-
sant prevalence decreased (6.6/1000 to 5.7/
1000). The use of the withdrawn antidepres-
sants (citalopram, escitalopram,
fluvoxamine, paroxetine, sertraline, and ven-
lafaxine) dropped by a third (3.1/1000 v
2.0/1000), but there was no change in fluox-
etine prevalence (2.1/1000 v 2.3/1000). The
use of tricyclic antidepressants declined
(2.0/1000 v 1.7/1000; P = 0.03).
Since 2003 fewer children and adoles-
cents have been prescribed antidepressants
in primary care, particularly the withdrawn
drugs. However, the use of fluoxetine and
non-selective SSRIs has not risen, implying
that they are not used as alternative
treatments.
Fewer prescriptions may be issued for
mild depression, or patients and their
parents are more aware, and therefore more
cautious, about antidepressant treatment.
Also, clinicians may choose psychotherapies,
such as cognitive behaviour therapy, over
antidepressants.
New referrals to child and adolescent
mental health services need to be measured
for health service planning. Further
research into the integrated management
of depression in childhood and adolescence
is urgently required so that adequate
infrastructure and resources can be
provided.
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Attributable lung cancer risk
from radon in homes may be
low
Editor—Darby et al provide compelling
evidence that indoor radon is an important
contributor to the risk of lung cancer.1 How-
ever, the derived estimate of radon attribut-
able lung cancers may have a low bias.
The authors estimate an increase in lung
cancer risk of 16% for each incremental 100
Bq/m3 of radon from a pooling of the Euro-
pean residential case-control studies. They
then estimate that radon may contribute to
9% of all lung cancers in those countries on
the basis of an estimated average radon con-
centration of 59 Bq/m3 for 29 European
countries. However, the relative risk per
Bq/m3 was determined in each study for an
exposure window of five to 35 years before
ascertainment of the disease.
Typically, lung cancer will occur after the
age of 55, so exposures received during child-
hood and young adulthood are not included.
This would not be a problem if exposures
occurring more than 35 years previously did
not contribute appreciably to lung cancer
risk. However, although the BEIR VI models
do incorporate a fall-off in risk with time, the
projected risk from childhood and young
adult exposures are still about the same as for
the population as a whole.2 3 As a result, more
than 30% of the radon contribution to the
population risk would be unaccounted for by
the case-control studies.
This conclusion is based on model
extrapolation; in reality, aside from very lim-
ited, and somewhat equivocal, data on
Chinese tin miners,4 no direct information is
available on risks from childhood exposures
to radon. Also, if radon levels before the 30
year measurement window were highly cor-
related with the estimated average levels
during the window, the error would be
reduced since the measured average expo-
sure rate would reflect the entire lifetime,
rather than just 30 years. This is unlikely to
be true in practice since people are unlikely
to have lived in the same houses during
childhood and early adulthood as they did
for the 35 years before the incidence of lung
cancer.
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Many patients may not
understand consent forms
Editor—McKinney et al highlight an
important issue—namely, the difficulty of
obtaining truly informed consent.1 This is a
process that most surgeons engage in every
day. The current requirement for informed
consent is backed by a written record of the
consent process in the form of a standard
consent form that has been distributed by
the Department of Health.2
Thousands of these forms are signed
daily, but do we as doctors ever stop to con-
sider how much of the form is read by
patients and for those who do read it, how
much of it is understood? Standard readabil-
ity measurements can be used to assess
readability, the Flesch readability ease score
being one of the most validated. A
document scoring 65 or above is considered
to be readable for most adults. I found that
the score for the entire text of the standard
UK consent form is 45.1 and that the “State-
ment of patient” section, which details
important patient concessions, is not much
better at 48.9. These scores correspond to a
“difficult college” level of literacy to under-
stand the document.
The Office for National Statistics pub-
lished data in 1996 that indicate that nearly
half of the UK adult population between the
ages of 16 and 65 have levels of literacy low
enough to significantly interfere with daily
work tasks.3 As clinicians and health
communicators, we must either shoulder the
additional burden of translating the current
consent form into understandable language
for a proportion of our patients or we
should consider using another, more patient
friendly form.
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